Novo Holdings Invests $72 Million in LanzaTech

Novo Holdings Acquires Catalent for $16.5 Billion

December 18, 2024

Healthcare Services

Novo Holdings A/S agreed to acquire Catalent, Inc. in an all-cash transaction valued at approximately $16.5 billion ($63.50 per share). The deal was later completed, and Catalent became a private company under Novo Holdings ownership; Novo Nordisk subsequently acquired Catalent’s three fill-finish sites in Italy, Indiana (USA), and Belgium.

Novo Holdings Invests £50m in Oxford Nanopore Technologies

August 1, 2024

Biotechnology

Novo Holdings has invested £50 million in UK-listed Oxford Nanopore Technologies via an equity issue and intends to make further share purchases in the secondary market. The investment is intended to support Oxford Nanopore's commercial growth and capability expansion in biopharmaceutical and biomanufacturing markets.

Novo Holdings Invests $40M in Evosep

January 9, 2023

Biotechnology

Novo Holdings has invested $40 million in Evosep to accelerate the commercialization and clinical application of Evosep’s standardized proteomics liquid chromatography platform. The funds will support product development and global expansion — particularly into the U.S. — and Novo Holdings’ principal, Stephen Van Helden, will join Evosep’s board.

Novo Holdings Leads €7M Seed Investment in Bactolife

April 20, 2021

Biotechnology

Novo Holdings (via its Novo Seeds team) led a €7 million seed round in Danish biotech Bactolife, committing €5 million to advance the company's pipeline. The funding will support development and scaling of Bactolife's anti-virulence Virulence Inactivating Proteins (VIPs) for animal and human gut health; Novo's Aleks Engel will join Bactolife's board.

Novo Holdings Acquires Double-Digit Stake in bioMASON

December 17, 2019

Manufacturing

Novo Holdings A/S made a multimillion-dollar, double-digit equity investment in US-based bioMASON to help commercialize its bacteria-grown biocement masonry products. As part of the deal Anders Spohr of Novo Holdings will join bioMASON's board as the company scales its sustainable concrete alternative for construction and infrastructure markets.

Novo Holdings Invests in Oxford Biomedica plc

May 28, 2019

Biotechnology

Novo Holdings A/S agreed to invest up to £53.5 million in new ordinary shares of Oxford Biomedica plc, taking up to a 10.1% stake. The proceeds will be used to repay an existing Oaktree debt facility in full and to scale Oxford Biomedica's LentiVector platform and proprietary product portfolio.